Atlas Trials

Anti-angiogenic Targeted Drugs Plus Rg3 to Improve the Efficacy of TACE for Unresectable Hepatocellular Carcinoma

Clinical trial NCT04523467 · UNKNOWN

Trial details

NCT number
NCT04523467
Sponsor
Eastern Hepatobiliary Surgery Hospital
Status
UNKNOWN
Phase
Not Applicable
Study type
INTERVENTIONAL
Hepatocellular Carcinoma
Start date
2020-12-01
Primary completion
2022-12-31
Enrollment
320

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.